Search

Importance: Oral squamous cell carcinoma (SCC) is a lethal malignant neoplasm with a high rate of tumor metastasis and recurrence. Accurate diagnosis, prognosis prediction, and metastasis detection can improve patient outcomes. Deep learning for clinical image analysis can be used for diagnosis and prognosis in cancers, including oral SCC; its use in these areas can improve patient care and outcome., Observations: This review is a summary of the use of deep learning models for diagnosis, prognosis, and metastasis detection for oral SCC by analyzing information from pathological and radiographic images. Specifically, deep learning has been used to classify different cell types, to differentiate cancer cells from nonmalignant cells, and to identify oral SCC from other cancer types. It can also be used to predict survival, to differentiate between tumor grades, and to detect lymph node metastasis. In general, the performance of these deep learning models has an accuracy ranging from 77.89% to 97.51% and 76% to 94.2% with the use of pathological and radiographic images, respectively. The review also discusses the importance of using good-quality clinical images in sufficient quantity on model performance., Conclusions and Relevance: Applying pathological and radiographic images in deep learning models for diagnosis and prognosis of oral SCC has been explored, and most studies report results showing good classification accuracy. The successful use of deep learning in these areas has a high clinical translatability in the improvement of patient care.

Importance: For patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant chemoradiation has been shown to improve long-term outcomes, but the treatment response varies among patients. Accurate pretreatment prediction of response remains an urgent need., Objective: To determine whether peritumoral radiomics features derived from baseline computed tomography images could provide valuable information about neoadjuvant chemoradiation response and enhance the ability of intratumoral radiomics to estimate pathological complete response., Design, Setting, and Participants: A total of 231 patients with esophageal squamous cell carcinoma, who underwent baseline contrast-enhanced computed tomography and received neoadjuvant chemoradiation followed by surgery at 2 institutions in China, were consecutively included. This diagnostic study used single-institution data between April 2007 and December 2018 to extract radiomics features from intratumoral and peritumoral regions and established intratumoral, peritumoral, and combined radiomics models using different classifiers. External validation was conducted using independent data collected from another hospital during the same period. Radiogenomics analysis using gene expression profile was done in a subgroup of the training set for pathophysiological explanation. Data were analyzed from June to December 2019., Exposures: Computed tomography-based radiomics., Main Outcomes and Measures: The discriminative performances of radiomics models were measured by area under the receiver operating characteristic curve., Results: Among the 231 patients included (192 men [83.1%]; mean [SD] age, 59.8 [8.7] years), the optimal intratumoral and peritumoral radiomics models yielded similar areas under the receiver operating characteristic curve of 0.730 (95% CI, 0.609-0.850) and 0.734 (0.613-0.854), respectively. The combined model was composed of 7 intratumoral and 6 peritumoral features and achieved better discriminative performance, with an area under the receiver operating characteristic curve of 0.852 (95% CI, 0.753-0.951), accuracy of 84.3%, sensitivity of 90.3%, and specificity of 79.5% in the test set. Gene sets associated with the combined model mainly involved lymphocyte-mediated immunity. The association of peritumoral area with response identification might be partially attributed to type I interferon-related biological process., Conclusions and Relevance: A combination of peritumoral radiomics features appears to improve the predictive performance of intratumoral radiomics to estimate pathological complete response after neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma. This study underlines the significant application of peritumoral radiomics to assess treatment response in clinical practice.